表紙
市場調查報告書
商品編碼
252329

全球人體生長荷爾蒙劑市場

Human Growth Hormone Drugs

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 335 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球人體生長荷爾蒙劑市場相關調查,市場概要及預測,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 市場預測
    • 重組人體生長荷爾蒙的發展
    • 專利失效在生技仿製藥的登場開啟道路
    • 技術創新席捲產業
    • 市場規模
    • 促進成長要素
    • 生長激素缺乏症的高罹患率
    • hGH置換療法的新適應症
    • 阻礙成長要素
    • 複雜的輸送系統
    • hGH治療的成本高
    • 償付確保的困難
    • 生技仿製藥收益擴大的威脅
    • 目前藥物存在有限的藥理學性差異
  • 市場趨勢與課題
  • 競爭環境
    • 非常整合的市場
    • 主要的已上市hGH產品概要
    • 開發中產品概要 其他
  • 人體生長荷爾蒙:概要
  • 近幾年的產業活動
  • 主要加入企業
    • Eli Lilly and Company
    • Ferring Holding SA
    • Genentech, Inc.
    • GeneScience Pharmaceuticals Co., Ltd.
    • Merck KgaA (Germany)
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sandoz International GmbH
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 其他
目錄
Product Code: MCP-7129

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026

The human growth hormone, which is also known as somatropin, is a peptide hormone that is secreted by pituitary gland, which regulates cell regeneration, cell growth, metabolism, and reproduction. The level of growth hormones should be optimum in human body for normal growth. It can be regulated by several factors such as sleep, stress, exercise, and lower levels of glucose. Human growth hormones help to control body composition, bone and muscle growth, sugar and fat metabolism, recovery from injuries, and body fluids. They also help in boosting muscle strength and performance. Improper levels of growth hormones may affect the quality of life, intensifying the risks of health disorders such as high levels of cholesterol, decreased bone density, and deficiency in growth hormones. While lower levels of the growth hormones result in fat accumulation in the human body, higher levels result in gigantism in children and short bowel syndrome and muscle-wasting disease in adults. With growing age, the human growth hormone levels decrease. This natural process of slowing down of the growth hormone production in human body has raised the interest in synthetic hormone therapies globally.

Amid the COVID-19 crisis, the global market for Human Growth Hormone Drugs estimated at US$3.3 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2026, growing at a CAGR of 3.5% over the analysis period. Subcutaneous, one of the segments analyzed in the report, is projected to grow at a 4% CAGR to reach US$2.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intramuscular segment is readjusted to a revised 3.1% CAGR for the next 7-year period. This segment currently accounts for a 23.7% share of the global Human Growth Hormone Drugs market.

The U.S. Market is Estimated at $1.3 Billion in 2021, While China is Forecast to Reach $285.1 Million by 2026

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2021. The country currently accounts for a 40.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$285.1 Million in the year 2026 trailing a CAGR of 5.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3% CAGR while Rest of European market (as defined in the study) will reach US$299.1 Million by the close of the analysis period.

The market is expected to witness growth owing to surge in cases related to pituitary dysfunction, and increasing number of health disorders in children, mainly owing to changes in food habits. Some other major factors that have been driving the market growth are advancement of recombinant HGH drugs, and increasing off-label use of human growth hormones. Also, increase in awareness with regards to treatment processes; increasing aging population; increasing neuropsychiatric cases; increasing funds by governments for research and development within the endocrinology sector; introduction of technological advancements within the healthcare sector for enhancing quality of services; increasing rate of consumption of the drugs in key applications. Additionally, initiatives adopted by private and public organizations for promoting healthcare-related policies and services in the under-developing and developed companies is also boosting market for human growth hormones globally. Also, demand from people for effective treatment processes and rise in disposable income among the urban population is likely to offer market growth opportunities. Increasing prevalence of adopting latest technologies in regards to pill production at low cost is also likely to positively impact market demand for human growth hormones. Increased FDA approvals are offering immense opportunities to companies for developing new, more effective drugs, with lesser side effects. The market will also benefit from increasing number of health disorders in children, mainly owing to changes in food habits. Also, increase in awareness in regards to treatment processes; increasing aging population; increasing neuropsychiatric cases; increasing funds by governments for research and development within the endocrinology sector; introduction of technological advancements within the healthcare sector for enhancing quality of services; increasing rate of consumption of the drugs in key applications; increasing approvals by FDA along with other government organizations; as well as increase in research organizations pertaining to the biotechnology field is driving market growth. Additionally, initiatives adopted by private and public organizations for promoting healthcare-related policies and services in the under-developing and developed companies is also boosting market for human growth hormones globally.

Intravenous Segment to Reach $304.8 Million by 2026

In the global Intravenous segment, USA, Canada, Japan, China and Europe will drive the 2.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$231.8 Million in the year 2020 will reach a projected size of US$269.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.4 Million by the year 2026.

Select Competitors (Total 46 Featured) -

  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • EMD Serono Inc.
  • Ferring Pharmaceuticals
  • Genentech, Inc (Roche)
  • GeneScience Pharmaceuticals Co. Ltd
  • Ipsen S.A.
  • LG Life Sciences
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer, Inc
  • Sandoz International GmbH (Novartis AG)
  • Strongbridge Biopharma
  • Teva Pharmaceutical Industries, Ltd

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Human Growth Hormone Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • A Prelude to Human Growth Hormones
    • Recombinant Human Growth Hormones
    • Evolution of Recombinant Human Growth Hormones (hGH)
    • COVID-19 Impact on Human Growth Hormone Drugs
  • GLOBAL MARKET OVERVIEW
    • Global Human Growth Hormone Drugs Market to Witness Steady Growth
    • List of Select Approved Prescription Daily-dose hGH Products by Indication
    • List of Select Approved Prescription Weekly-dose hGH Products by Indication
    • Subcutaneous Route Dominates Human Growth Hormone Drugs Market
    • Growth Hormone Deficiency Application Leads the Human Growth Hormone Drugs Market
    • North America and Europe Dominate, Asia-Pacific to Witness Fastest Growth
    • Market Restraints
    • Competition
    • Leading Recombinant hGH Products in the Global Market (2020): Annual Sales in US$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen
    • Global Recombinant hGH Products Market (2020): Market Share of Leading Players
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Prevalence of Growth Hormone Deficiency Disorders
    • Pediatric GHD Rules, while Adult GHD Remains Underserved
    • Worldwide Recombinant Human Growth Hormone Market by Indication (2020): Percentage Breakdown of Value Sales for Pediatric GHD; Adult GHD, Turner Syndrome & Idiopathic Short Stature; and Others
    • Long-Acting hGH Drugs - A Game Changer for the Human Growth Hormone Drugs Market
    • Approval of Novo Nordisk's Once-Weekly Sogroya to Transform the Market Landscape
    • Other Noteworthy Developments in the Long Acting hGH Space
    • Patent Expiry Paves Way for the Emergence of Biosimilars
    • Strong Innovation Drive Takes Hold of the hGH Industry
    • Manufacturers Bet on Novel Drug Delivery Technologies
    • Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
    • Needle-less Drug Delivery Systems to Wipe Out of Syringes
    • Drug Delivery Device Options for Marketed hGH Products
    • Major Growth Restraining Factors
    • Complex Delivery System
    • High Cost of hGH Treatment
    • Biosimilars Threaten Revenue Growth Erosion
  • PIPELINE ANALYSIS
    • Select Daily and Long-Acting Human Growth Hormone Products List in Phase III Pipeline
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 19: World Recent Past, Current & Future Analysis for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Specialty Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 25: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 28: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 31: World Recent Past, Current & Future Analysis for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Turner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 34: World Recent Past, Current & Future Analysis for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Idiopathic Short Stature (ISS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 37: World Recent Past, Current & Future Analysis for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Prader-Willi Syndrome (PWS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 43: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 46: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 49: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • CANADA
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 55: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 58: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • JAPAN
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 61: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Japan 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 67: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • CHINA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 70: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: China 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 73: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: China Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: China 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 76: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: China 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • EUROPE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 79: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 85: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 88: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • FRANCE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 91: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: France 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 94: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: France Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: France 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 97: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: France Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: France 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • GERMANY
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 100: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Germany 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 103: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Germany Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Germany 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 106: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Germany Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Germany 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 109: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Italy 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 112: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Italy Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Italy 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 115: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Italy Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Italy 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 118: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: UK 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 121: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: UK Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: UK 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 124: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: UK Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: UK 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 127: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Spain Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Spain 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 130: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Spain Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Spain 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 133: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Spain Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Spain 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 136: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Russia Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Russia 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 139: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Russia Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Russia 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 142: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Russia Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Russia 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 145: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 148: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 151: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 154: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 157: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 160: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
    • TABLE 163: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Latin America Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 166: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Latin America Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 169: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Latin America Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
    • TABLE 172: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 175: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Middle East Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 178: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Middle East Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027
  • AFRICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
    • TABLE 181: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Africa Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Africa 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2012, 2021 & 2027
    • TABLE 184: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Africa Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Africa 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
    • TABLE 187: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Africa Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Africa 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46